Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06185192 · ClinicalTrials.gov registry record · NA

Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c

A NA study of Diabetes, sponsored by Viome.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06185192 is a NA study of Diabetes that is actively recruiting participants, run by Viome. The registered enrollment target is 100 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06185192, a NA study of Diabetes, is actively recruiting participants, sponsored by Viome.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Viome's Precision Nutrition Program (VPNP)

Study Locations (1)

Washington

  • Viome Life Sciences - Bothell

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-12-13
Est. Completion 2026-12
Phase NA

Sponsor

Viome

18 total trials

What the Registry Record Tells You About NCT06185192

The ClinicalTrials.gov registry entry for NCT06185192 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Viome, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Viome's Precision Nutrition Program (VPNP) is the first listed.

NCT06185192 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06185192 about?

NCT06185192 is a clinical study titled "Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c". This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.

What is the current status of trial NCT06185192?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-12-13. Estimated completion is 2026-12.

What conditions does trial NCT06185192 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT06185192?

The interventions under investigation include: Viome's Precision Nutrition Program (VPNP) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06185192?

This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06185192 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.